Silexion Therapeutics Statistics
Want to see SLXN full AI Analyst Report?
Silexion Therapeutics (SLXN) Stock Statistics & Valuation Metrics
Total Valuation
Silexion Therapeutics has a market cap or net worth of $1.69M. The enterprise value is -$3.18M.
- Market Cap
- $1.69M
- Enterprise Value
- -$3.18M
Share Statistics
Silexion Therapeutics has 633,896 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 633,896
- Owned by Insiders
- 90.83%
- Owned by Institutions
- ―
Financial Efficiency
Silexion Therapeutics’s return on equity (ROE) is -4.58 and return on invested capital (ROIC) is 250.74%.
- Return on Equity (ROE)
- -4.58
- Return on Assets (ROA)
- -1.65
- Return on Invested Capital (ROIC)
- 250.74%
- Return on Capital Employed (ROCE)
- 2.61
- Revenue Per Employee
- 0
- Profits Per Employee
- -850.86K
- Employee Count
- 14
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Silexion Therapeutics is -0.00. Silexion Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.12
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.03
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Silexion Therapeutics had revenue of 0 and earned -11.91M in profits. Earnings per share was -2150.40.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- 11.63M
- Pretax Income
- -11.91M
- Net Income
- -11.91M
- EBITDA
- -11.88M
- Earnings Per Share (EPS)
- -2150.40
Cash Flow
In the last 12 months, operating cash flow was -11.70M and capital expenditures -44,000, giving a free cash flow of -11.74M billion.
- Operating Cash Flow
- -11.70M
- Free Cash Flow
- -11.74M
- Free Cash Flow per Share
- -63.50
Dividends & Yields
Silexion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22452.96%
- Earnings Yield
- -3612.95%
Stock Price Statistics
- Beta
- 0.13
- 52-Week Price Change
- -99.71%
- 50-Day Moving Average
- 5.94
- 200-Day Moving Average
- 131.00
- Relative Strength Index (RSI)
- 28.68
- Average Volume (3m)
- 430.15K
Important Dates
Silexion Therapeutics upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Silexion Therapeutics as a current ratio of 2.41, with Debt / Equity ratio of 17.98%
- Current Ratio
- 2.41
- Quick Ratio
- 2.41
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- 0.46
- Interest Coverage Ratio
- 894.77
Taxes
In the past 12 months, Silexion Therapeutics has paid 3,000 in taxes.
- Income Tax
- 3,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Silexion Therapeutics EV to EBITDA ratio is 0.32, with an EV/FCF ratio of 0.37.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.32
- EV to Free Cash Flow
- 0.37
- EV to Operating Cash Flow
- 0.37
Balance Sheet
Silexion Therapeutics has $4.76M in cash and marketable securities with $374.00K in debt, giving a net cash position of $4.39M billion.
- Cash & Marketable Securities
- $4.76M
- Total Debt
- $374.00K
- Net Cash
- $4.39M
- Net Cash Per Share
- $6.92
- Tangible Book Value Per Share
- $16.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Silexion Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 36.44%
Scores
- Smart Score
- ―
- AI Score
- 41
